| Literature DB >> 30467012 |
Abstract
In recent decades, the field of drug safety/pharmacovigilance (PV) has advanced dramatically in some ways and yet has remained stagnant or progressed slowly in others. One way to assess the PV landscape is to view it through both a regulatory lens and a science and technology lens. This commentary highlights some of the current PV issues that can be resolved by sustained collaboration among all relevant stakeholders.Keywords: adverse events; drug safety; pharmacovigilance; regulatory
Mesh:
Year: 2018 PMID: 30467012 DOI: 10.1016/j.clinthera.2018.09.016
Source DB: PubMed Journal: Clin Ther ISSN: 0149-2918 Impact factor: 3.393